CJC-1295 vs Tesamorelin
CJC-1295 (GHRH analogue)
A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release.
Tesamorelin (stabilized GHRH analogue)
An FDA-approved GHRH analogue that reduces visceral fat, now also studied for cognition in older adults at Alzheimer's risk.
| Attribute | CJC-1295 | Tesamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA status | Not FDA-approved | FDA-approved (Egrifta) for HIV-associated lipodystrophy |
| Half-life | ~6-8 days (DAC version) | ~26-38 minutes |
| Molecular weight | 3,647.2 Da | 5,135.9 Da |
| Mechanism | Activates the GHRH receptor on the pituitary to increase growth hormone secretion; albumin binding prolongs its activity. | Activates pituitary GHRH receptors to stimulate physiological, pulsatile growth hormone release, preserving hypothalamic feedback. |
| Legal status (US) | Not approved; research use only | FDA-approved for a specific indication, prescription only |
Frequently asked questions
What is the difference between CJC-1295 and Tesamorelin?
CJC-1295: A modified GHRH analogue engineered for an extended half-life, promoting sustained growth hormone and IGF-1 release. Tesamorelin: An FDA-approved GHRH analogue that reduces visceral fat, now also studied for cognition in older adults at Alzheimer's risk.
Which has stronger research evidence, CJC-1295 or Tesamorelin?
CJC-1295 is rated Moderate and Tesamorelin is rated Strong for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are CJC-1295 and Tesamorelin FDA-approved?
CJC-1295: Not FDA-approved. Tesamorelin: FDA-approved (Egrifta) for HIV-associated lipodystrophy.
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.